Aripiprazole Tablet
Product Images NDC 82804-235

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 82804-235). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image 1 (Figure 1)

Image 1 (Figure 1)
This is a figure showing the impact of other drugs on Aripiprazole pharmacokinetics. It illustrates changes in Aripiprazole concentration relative to a reference point when combined with different drugs. The chart appears to include various drug interactions and their effects on Aripiprazole levels.*
FDA Label Image

Image 2 (Figure 2)

Image 2 (Figure 2)
This is a bar graph showing the effect of other drugs on the pharmacokinetics of Dehydro-Aripiprazole. The graph displays changes in pharmacokinetics relative to the reference (without referencing drug) at different time points. The impact of various drugs on the metabolism of Aripiprazole is being analyzed.*
FDA Label Image

Image 3 (Figure 3)

Image 3 (Figure 3)
This is a figure depicting the effect of Aripiprazole on the pharmacokinetics of various other drugs. The table includes the fold change and 90% confidence interval for different drugs such as dextromethorphan, omeprazole, venlafaxine, and lorazepam, among others. The chart displays the change relative to the reference (without the interacting drug) on the x-axis and the drugs on the y-axis.*
FDA Label Image

Image 4 (Figure 4)

Image 4 (Figure 4)
This information is about the effect of intrinsic factors on Aripiprazole pharmacokinetics in special populations. It includes details on how CYP2D6 poor metabolizers, gender, age, hepatic impairment, and renal impairment can impact the Aripiprazole pharmacokinetics. The text also mentions comparisons between different groups for AUC and Cmax values.*
FDA Label Image

Image 5 (Figure 5)

Image 5 (Figure 5)
This is a table showing the effect of intrinsic factors on Dehydro-aripiprazole pharmacokinetics. It includes comparisons such as poor vs. extensive metabolizer, female vs. male, age categories (18-64 vs. 65 years old), hepatic impairment (moderate vs. normal), and renal impairment. The data presented in the table are related to the AUC and Cmax values for Dehydro-aripiprazole.*
FDA Label Image

Fig-6 (Figure 6)

Fig-6 (Figure 6)
The text displays the Kaplan-Meier estimation of the cumulative proportion of patients with relapse in a schizophrenia study. It compares the relapse rates of patients on Aripriprazole versus Placebo over time, with the days from randomization provided on the x-axis. The graph shows the proportion of patients with relapse and the number of subjects at risk at various time points throughout the study.*
FDA Label Image

7 (Figure 7)

7 (Figure 7)
The figure shows the Kaplan-Meier estimation for the cumulative proportion of patients with relapse in Bipolar Study 7 comparing Avipriprazole and Placebo. The proportion with relapse is graphed over time, and the number of subjects at risk for each treatment group is listed at different time points. This figure provides valuable information about the relapse rates and treatment outcomes in the study.*
FDA Label Image

8 (Figure 8)

8 (Figure 8)
This is a Kaplan-Meier estimation graph showing the cumulative proportion of patients with relapse to any mood event in a Bipolar Study 8. The x-axis represents the days from randomization while the y-axis represents the proportion with relapse. The graph compares Aripiprazole and Placebo treatments, with data points indicating the proportion of patients with relapse over time. The number of subjects at risk is also provided for each timepoint.*
FDA Label Image

9 (Figure 9)

9 (Figure 9)
FDA Label Image

82804-235-90 (Image 01)

82804-235-90 (Image 01)
This text provides details about Aripiprazole 5mg tablets, including the dosage, quantity, manufacturer, product description, storage instructions, and important warnings. It also mentions the NDC numbers, expiration dates, and lot numbers for different quantities of the medication. The medication guide is recommended to be given to each patient. The tablets are round, white to off-white, uncoated, and imprinted with the numbers "5" and "17". It mentions the manufacturer as TORRENT PHARMACEUTICALS LTD. from India. The medication should be stored at 20°-25°C (68°-77°F) and kept away from children. The tablets are relabeled by Proficient Rx LP in Thousand Oaks, CA.*
FDA Label Image
Image (Mg Logo)
FDA Label Image
Logo (Pi Logo)
FDA Label Image

Description Image (Structure)

Description Image (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.